Physician profile
Mary Perry
NPI 1992182745
$870.62
in general payments reported to CMS, 2019-2025
14 companies · $78.52 in 2025
The $78.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.38 · 2020: $27.08 · 2021: $62.53 · 2022: $13.22 · 2023: $270 · 2024: $362 · 2025: $78.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.01 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $117.18 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $109.42 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $108.68 | 2023-2025 | |
| Amgen INC. | $107.56 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $74.05 | 2023-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $59.34 | 2019-2021 | |
| Abbvie INC. | $43.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $37.66 | 2023-2024 | Farxiga, Airsupra |
| Astellas Pharma US INC | $24.69 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $15.71 | 2020 | |
| Glaxosmithkline, LLC. | $14.19 | 2023 | Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $12.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.